| CAMK2A Gene | |
|---|---|
| Process | Mechanism |
| **[LTP](/mechanisms/long-term-potentiation) induction** | CaMKII autophosphorylation at T286 |
| **LTD induction** | Protein phosphatases reverse CaMKII action |
| **[LTP](/mechanisms/long-term-potentiation) maintenance** | Persistent CaMKII activity |
| **Memory consolidation** | CREB activation, gene transcription |
| Approach | Agent |
| **CaMKII inhibitors** | KN-62, AIP |
| **CaMKII activators** | Peptide fragments |
| **BDNF analogs** | BDNF, NT-3 |
| **PDE inhibitors** | Ibudilast |
| **Gene therapy** | AAV-CAMK2A |
| Biomarker | Sample |
| p-CaMKII (T286) | Brain tissue, CSF |
| CaMKII activity | Brain tissue |
| p-NR2B (S1303) | Brain tissue |
| Associated Diseases | ALS, Als, Depression, Ms, PARKINSON |
| KG Connections | 47 edges |
Introduction
Camk2A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
flowchart TD
CAMK2A["CAMK2A"] -->|"activates"| Hepatic_Mitochondrial_Oxidatio["Hepatic Mitochondrial Oxidation"]
CAMK2A["CAMK2A"] -->|"involved in"| Neuroregeneration["Neuroregeneration"]
Camk2A["Camk2A"] -->|"promotes"| hepatic_mitochondrial_oxidatio["hepatic mitochondrial oxidation"]
Camk2A["Camk2A"] -->|"promotes"| intrahepatic_lipolysis["intrahepatic lipolysis"]
Camk2A["Camk2A"] -->|"mediates"| hepatic_fat_metabolism["hepatic fat metabolism"]
CAMK2A["CAMK2A"] -->|"involved in"| Necroinflammation["Necroinflammation"]
CAMK2A["CAMK2A"] -->|"involved in"| Neuronal_Regeneration["Neuronal Regeneration"]
CAMK2A["CAMK2A"] -->|"activates"| Intrahepatic_Lipolysis["Intrahepatic Lipolysis"]
Camk2A["Camk2A"] -->|"regulates"| neuroregeneration["neuroregeneration"]
Camk2A["Camk2A"] -->|"regulates"| gluconeogenesis["gluconeogenesis"]
CAMK2A["CAMK2A"] -->|"mediates"| Gluconeogenesis["Gluconeogenesis"]
CAMK2A["CAMK2A"] -->|"treats"| MTOR["MTOR"]
CAMK2A["CAMK2A"] -->|"activates"| PARP1["PARP1"]
CAMK2A["CAMK2A"] -->|"participates in"| neurotrophin_signaling["neurotrophin signaling"]
style CAMK2A fill:#4fc3f7,stroke:#333,color:#000The CAMK2A gene encodes the alpha subunit of Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII), one of the most abundant proteins in the brain, constituting up to 2% of total brain protein. CaMKII is a serine/threonine protein kinase that functions as a molecular decoder of calcium signals, playing essential roles in synaptic plasticity, learning, and memory. The CAMK2A isoform is predominantly expressed in excitatory neurons of the forebrain, particularly in the hippocampus and cerebral cortex. Dysregulation of CaMKII signaling is implicated in Alzheimer’s disease, Parkinson’s disease, epilepsy, intellectual disability, and various other neurological disorders.
Gene Structure
-
Gene length: ~95 kb
-
Exons: 13 coding exons
-
Promoter: Activity-dependent, regulated by CREB
-
Alternative splicing: Generates multiple isoforms
Isoforms
-
CaMKIIα: Brain-specific, 12 subunits
-
CaMKIIβ: Brain and muscle, regulates localization
-
CaMKIIγ/δ: Ubiquitous expression
Protein Structure
CaMKII forms a holoenzyme with 12 subunits arranged in two stacked hexameric rings:
Subunit Structure
-
N-terminal catalytic domain: Kinase activity
-
Regulatory domain: Autoinhibitory, calmodulin-binding
-
Association domain: Multimerization
-
C-terminal variable region: Targeting elements
Key Features
-
T286 autophosphorylation: Calcium-independent activity
-
T305/T306: Inhibition of calmodulin binding
-
F506: F-site for calmodulin trapping
Normal Function
Synaptic Plasticity
Molecular Mechanisms
-
Calcium influx: NMDA receptors, voltage-gated calcium channels
-
Calmodulin binding: Calcium-calmodulin activates CaMKII
-
Autophosphorylation: T286 becomes phosphorylated
-
Calcium-independent activity: Truncated CaMKII remains active
-
Substrate phosphorylation: NR2B, AMPA receptors, CREB
-
Synaptic targeting: PSD-95, NMDA receptor complexes
Brain Region Distribution
-
Hippocampus: Highest expression in CA1 and CA3 pyramidal neurons
-
Cerebral cortex: Layers II-III and V pyramidal neurons
-
Striatum: Medium spiny neurons
-
Amygdala: Principal neurons
-
Thalamus: Relay neurons
Cell Type Specificity
-
Excitatory glutamatergic neurons: Very high
-
Inhibitory GABAergic neurons: Low
-
Astrocytes: Minimal
-
Oligodendrocytes: Minimal
Role in Neurodegeneration
Alzheimer’s Disease
CaMKII signaling is significantly impaired in Alzheimer’s disease at multiple levels:
-
Reduced CaMKII activity: Postmortem AD brain shows 40-60% reduction
-
Tau hyperphosphorylation: CaMKII can phosphorylate tau at multiple sites (Ser262, Thr231)
-
Synaptic dysfunction: Impaired LTP correlates with memory deficits
-
Aβ toxicity: Aβ oligomers disrupt CaMKII localization
-
NMDA receptor dysregulation: Altered NR2B phosphorylation
Therapeutic strategies:
-
CaMKII activators (experimental)
-
BDNF to restore CaMKII signaling
-
PDE inhibitors to enhance cAMP/CaMKII pathway
Parkinson’s Disease
-
Dopaminergic signaling: CaMKII modulates D1/D2 receptor signaling
-
L-DOPA-induced dyskinesia: CaMKII hyperactivity in striatum
-
α-synuclein toxicity: CaMKII may phosphorylate α-syn
-
Neuroprotection: CaMKII activation provides dopaminergic protection
Epilepsy
-
Gain-of-function mutations: Cause early-onset epileptic encephalopathy
-
Seizure-induced activation: CaMKII upregulation after seizures
-
Synaptic hyperexcitability: Enhanced glutamate release
-
Therapeutic targeting: CaMKII inhibitors in development
Intellectual Disability and Autism
-
De novo mutations: Associated with ID and ASD
-
Synaptic dysfunction: Impaired activity-dependent plasticity
-
Cognitive deficits: Memory and learning impairments
Stroke and Traumatic Brain Injury
-
Ischemic injury: CaMKII activation during ischemia
-
Excitotoxicity: Excessive calcium influx dysregulates CaMKII
-
Neuroprotection: CaMKII inhibition may reduce damage
-
Recovery: CaMKII activity important for rehabilitation
Therapeutic Targeting
Challenges
-
CNS penetration: Many inhibitors don’t cross BBB
-
Isoform specificity: Pan-CaMKII vs isoform-selective
-
Therapeutic window: Both too much and too little are problematic
Biomarkers
Animal Models
Knockout Mice
-
Camk2a null: LTP deficits, spatial memory impairment
-
T286A knockin: LTP impairment, no memory consolidation
Transgenic Models
-
CaMKIIa-Cre: Neuron-specific expression
-
Conditional knockout: Temporal control of deletion
Disease Models
-
5xFAD mice: CaMKII deficits
-
α-syn models: CaMKII activation studies
-
TBI models: CaMKII in injury and recovery
Research Directions
-
Blood-brain barrier penetrating CaMKII modulators
-
Activity-dependent CaMKII monitoring
-
Personalized medicine based on CAMK2A variants
-
Combination therapies targeting multiple synaptic pathways
-
Gene therapy for CAMK2A deficiency
See Also
See Also
External Links
Background
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.